10

Loading video...

Hollie Silverman

By Hollie Silverman

News Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


Federal authorities have dismantled what the Drug Enforcement Administration (DEA) says is the first known large-scale domestic laboratory in the United States used to manufacture nitazenes, a class of powerful synthetic opioids that can match or exceed fentanyl in potency.

The East Baton Rouge Sheriff's Office (EBRSO) discovered the laboratory in a Baton Rouge home on November 12 during a drug-trafficking investigation. Investigators initially believed they had uncovered a fentanyl operation, but additional DEA forensic testing found that liquid inside the lab's main reactor contained etonitazene, a particularly potent member of the nitazene family.

The discovery comes as federal officials warn of an evolving illicit drug supply in which powerful synthetic substances are increasingly mixed with fentanyl and other narcotics or pressed into counterfeit prescription pills.

Read More on News

Newsweek reached out to the DEA, the EBRSO and the U.S. Attorney's Office for the Middle District of Louisiana by email Saturday for more information.

The Raid and Arrest

Sheriff's deputies uncovered the facility while investigating suspected drug trafficking involving 34-year-old Torrey Lewis Jr. of Baton Rouge.

Authorities executed three search warrants on November 12 and discovered what the DEA described as a sophisticated clandestine laboratory at a residence on Cottage Hill Drive. The facility housed roughly $250,000 worth of professional-grade equipment, including a 100-liter reactor system, specialized temperature-control units and an industrial evaporator.

The main reactor held about 15.3 gallons of liquid. DEA forensic chemists from the agency's South Central Laboratory in Dallas assisted with the investigation, and test results received on Wednesday confirmed the presence of etonitazene.

During the operation, authorities also reported seizing approximately 22.5 grams of fentanyl, 3 grams of cocaine, two rifles, $8,531 in cash and additional drug-manufacturing and distribution equipment.

Jail records show the suspect was ordered held without bond on charges including operating a clandestine drug laboratory, possession with intent to distribute a Schedule II substance, illegal carrying of a weapon with drugs, possession of drug paraphernalia and money laundering. A commissioner set a $200,000 cash or surety bond on a separate Schedule I distribution or possession-with-intent charge added November 19. It was not immediately clear if Lewis had an attorney who could comment on his behalf.

A container of Narcan, or naloxone, sits on tree roots at a longstanding homeless encampment in Bellingham, Washington, on February 8, 2024. | AP Photo/Lindsey Wasson, File

...

A Growing Synthetic Threat

Nitazenes carry a heightened overdose risk because users are often unaware the compounds have been mixed into illicit drugs or counterfeit pills. While the opioid-reversal medication naloxone can treat a suspected nitazene overdose, the DEA has warned that multiple doses may be required.

In May, the DEA issued a public safety advisory warning that illicit fentanyl was increasingly being combined with synthetic additives, including nitazenes, xylazine, cychlorphine and medetomidine. The agency has identified 22 unique nitazene compounds since 2020, 21 of which are classified as Schedule I controlled substances. Officials noted that new nitazene variations tend to emerge on the illicit market as law enforcement and drug scheduling put pressure on existing analogues.

Louisiana has emerged as a particular hotspot for the substance. More than 80 percent of the etonitazene exhibits seized by the DEA nationwide this year originated in the state, according to Louisiana State Police Crime Laboratory data cited by the agency.

The emergence of nitazenes marks the latest phase in a U.S. opioid crisis that has killed hundreds of thousands of Americans and prompted sprawling legal battles, including a $26 billion settlement involving Johnson & Johnson and three major drug distributors, as well as a subsequent $7.4 billion settlement agreement involving Purdue Pharma and the Sackler family.

How Strong Is Nitazene?

There is no single potency level for nitazenes because the term refers to a family of related synthetic opioids whose strength varies depending on the specific compound.

The DEA says nitazenes can match or vastly exceed fentanyl's potency. Etonitazene, the substance detected in the Baton Rouge laboratory, is among the particularly potent members of the drug class.

Nitazenes act on opioid receptors and, like fentanyl and other opioids, can cause potentially fatal respiratory depression. Their potency creates an additional danger when the substances are unknowingly consumed in counterfeit pills or illicit drugs containing multiple substances.

The DEA warned that nitazenes and other emerging substances are being found in an increasingly unpredictable illicit drug supply. The agency said the compounds can be mixed into counterfeit pills or fentanyl powder without a user's knowledge.

That can also complicate overdose response. The DEA has warned that highly potent synthetic opioids such as nitazenes may require several doses of naloxone to reverse their effects.

Newsweek*’s reporters and editors used Martyn, our AI assistant, to produce this story. Learn more about Martyn here.* Contact Newsweek editors for this story: Steve Mollman and Anthony Murray.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines